Xinkuo^® Doxazosin Mesylate Extended Release Tablets were approved for market as a Class 4 chemical drug in July 2023 and are clinically used for the treatment of benign prostatic hyperplasia (BPH) and hypertension. Xinkuo^® effectively blocks α1A/α1D receptors, providing strong relief for both urination and storage symptoms. With GITS technology, it ensures stable drug concentration and enhanced safety. Unlike other Doxazosin formulations, Xinkuo® passed the consistency evaluation upon market launch, demonstrating bioequivalence to the original product, providing a new treatment option for BPH and hypertension patients.